Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs

Chest

Volumn 134, Issue 5, 2008, Pages 1027-1032

  Suzuki, Yuzo ^a   Miwa, Seiichi ^b,c   Shirai, Masahiro ^b   Ohba, Hisano ^b   Murakami, Miho ^b   Fujita, Kaoru ^b   Suda, Takafumi ^a   Nakamura, Hirotoshi ^a   Hayakawa, Hiroshi ^b   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

^c NONE   (Japan)

Author keywords

Drug adverse reaction; Drug lymphocyte stimulation test; Drug provocation test; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG ERUPTION; DRUG FEVER; FEMALE; HEPATITIS; HUMAN; LOEFFLER PNEUMONIA; LYMPHOCYTE TRANSFORMATION TEST; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROVOCATION TEST; SENSITIVITY ANALYSIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 55849123997     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.07-3088     Document Type: Article

References (26)

1. Treatment of tuberculosis. Joint Statement of the American Thoracic Society (ATS), Center for Disease Control and Prevention, and Infectious Diseases Society of America. Am J Respir Crit Care Med 2003; 167:603-662
2. East African/BMJ Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1973; 1:1331-1339
3. British Thoracic Association. A controlled trial of six months of chemotherapy in pulmonary tuberculosis: second report; results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982; 126:460-462
4. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:423-430
5. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-952
6. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112:397-406
7. Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994; 33:387-401
8. Dutt AK, Moers D, Stead WW. Undesirable side-effects of isoniazid and rifampin on largely twice weekly short-course chemotherapy for tuberculosis. Am Rev Respir Dis 1994; 128:419-424
9. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003; 68:1781-1790
10. Gruchalla RS. Drug allergy. J Allergy Clin Immunol 2003; 111:548-559
11. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59:809-820
12. Beeler A, Pichler WJ. In vitro tests of T-cell-mediated drug hypersensitivity. In: Pichler WJ, ed. Drug hypersensitivity 2007; 380-390
13. Everness KM, Gawkrodger DJ, Botham PA, et al. The discrimination between nickel-sensitive and non-nickel-sensitive subjects by an in vitro lymphocyte transformation test. Br J Dermatol 1990; 122:293-298
14. Luque I, Leyva L, Jose Torres M, et al. In vitro T-cell responses to β-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56:611-618
15. Warrington RJ, McPhilips-Feener S, Rutherford WJ. The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clin Allergy 1982; 12:217-222
16. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27:175-181
17. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439-1444
18. Schreiber J, Zissel G, Greinert U, et al. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. Eur J Med Res 1999; 25:67-71
19. Miyazawa T, Doi M, Mineshita M, et al. Comparison of lymphocyte stimulation test results and challenge test results in 19 cases of antituberculous drug-induced allergy. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31:920-923
20. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854-863
21. Barna BP, Gogate P, Deodhar SD, et al. Lymphocyte transformation and radioallergosorbent tests in drug hypersensitivity. Am Soc Clin Pathol 1980; 73:172-176
22. Berg PA, Brattig N, Diao GJ, et al. Diagnose arzneimittelbedingter Nebenwirkungen mit Hilfe des Lymphozytentransformationstests. Allergologie 1983; 6:77-81
23. Matsuno O, Okubo T, Hiroshige S, et al. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med 2007; 212:49-53
24. Schaberg T, Rebhan K, Lode H. Risk factor for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9:2026-2030
25. Yee D, Valiqutte C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477
26. Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line antituberculosis drug regimen. Int J Tuberc Lung Dis 2007; 11:868-875